Clinical Trial

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm exploratory trial conducted by Xuanwu Hospital, Capital Medical University, aiming to evaluate the efficacy and safety of everolimus monotherapy in adult patients with vascular malformations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-22; most recent amendment 2025-09-02.
Trial Details
NCT Number NCT07037238
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Vascular Malformations
Enrollment 10 participants
Start Date 2025-07-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-05